Edesa Biotech, Inc. (EDSA) NASDAQ
6.83
+0.14(+2.09%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Edesa Biotech, Inc.
Sector
Healthcare
Industry
Biotechnology
Employees
16
First IPO Date
June 21, 2010
Key Executives
| Name | Title | Pay | Year Born |
| Pardeep Nijhawan FRCPC | Chief Executive Officer, Company Secretary & Director | 483,828 | 1971 |
| Peter John Weiler | Chief Financial Officer | 310,558 | 1969 |
| Michael J. Brooks | President | 450,206 | 1979 |
Description
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
